Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.68
(-7.76%)
USD 0.68
(-7.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -161.89 Million | -88.85 Million | -87.01 Million | -142.96 Million | 113.8 Million | -148.6 Million |
| Net Income | -177.11 Million | -101.94 Million | -87.75 Million | -58.57 Million | 130.13 Million | -120.54 Million |
| Depreciation & Amortization | 554 Thousand | 427 Thousand | 292 Thousand | 2.93 Million | 3.65 Million | 3.68 Million |
| Deferred income taxes | -5.09 Million | - | 49 Thousand | -110 Thousand | -6.01 Million | - |
| Stock-based compensation | 14.34 Million | 11.52 Million | 10.57 Million | 13.27 Million | 14.21 Million | 11.69 Million |
| Change in working capital | 2.65 Million | 402 Thousand | -10.23 Million | 31.07 Million | -58.28 Million | -44.77 Million |
| Other non-cash items | 2.76 Million | 744 Thousand | 54 Thousand | -131.57 Million | 30.1 Million | 1.33 Million |
| Investing Cash Flow | -49.94 Million | -71.07 Million | 2.11 Million | 380.75 Million | -155.85 Million | 169.57 Million |
| Investments in PPE | -470 Thousand | -1.32 Million | -1.22 Million | -87 Thousand | -70 Thousand | -95 Thousand |
| Acquisitions | 49.47 Million | 69.75 Million | -3.33 Million | 11.01 Million | 155.78 Million | - |
| Investment purchases | -223.34 Million | -133.94 Million | -34.26 Million | -58.55 Million | -322.38 Million | -119.98 Million |
| Sales/Maturities of investments | 173.87 Million | 64.19 Million | 37.59 Million | 268 Million | 166.6 Million | 289.65 Million |
| Other Investing Activities | -49.47 Million | -69.75 Million | 3.33 Million | 160.38 Million | -155.78 Million | 169.67 Million |
| Financing Cash Flow | 187.96 Million | 142.2 Million | 22.7 Million | -147.63 Million | -2.22 Million | -2.24 Million |
| Debt repayment | -49.96 Million | -48.86 Million | -11.7 Million | -216.58 Million | -1.28 Million | -14.53 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -824 Thousand | -864 Thousand | -2.67 Million | -1.02 Million | -941 Thousand | -972 Thousand |
| Common Stock Issuance | 138.82 Million | 94.2 Million | 37.08 Million | 69.97 Million | - | 732 Thousand |
| Other Financing Activities | 138.82 Million | 97.73 Million | 11.7 Million | 216.58 Million | -2.22 Million | 12.52 Million |
| Accounts receivables | -982 Thousand | -14 Thousand | 381 Thousand | 53.22 Million | -50.6 Million | -1.09 Million |
| Accounts payables | 6.45 Million | 76 Thousand | -14.15 Million | -20.96 Million | 20.09 Million | -18.85 Million |
| Inventory | -381 Thousand | - | - | 345 Thousand | 437 Thousand | -2.73 Million |
| Other working capital | -2.43 Million | 340 Thousand | 3.54 Million | -1.52 Million | -28.21 Million | -22.08 Million |
| Cash at beginning of period | 46.34 Million | 64.06 Million | 126.26 Million | 36.11 Million | 80.38 Million | 61.66 Million |
| Cash at end of period | 22.46 Million | 46.34 Million | 64.06 Million | 126.26 Million | 36.11 Million | 80.38 Million |
| Capital Expenditure | -470 Thousand | -1.32 Million | -1.22 Million | -87 Thousand | -70 Thousand | -95 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -23.88 Million | -17.72 Million | -62.19 Million | 90.15 Million | -44.27 Million | 18.72 Million |
| Free Cash Flow | -162.36 Million | -90.17 Million | -88.23 Million | -143.05 Million | 113.73 Million | -148.7 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -53.42 Million | -48.39 Million | -177.11 Million | -48.24 Million | -50.52 Million | -44.9 Million |
| Depreciation & Amortization | 139 Thousand | 144 Thousand | 554 Thousand | 147 Thousand | 151 Thousand | 144 Thousand |
| Deferred income taxes | - | - | -5.09 Million | -6.89 Million | - | - |
| Stock-based compensation | 4.85 Million | 4.3 Million | 14.34 Million | 3.21 Million | 3.89 Million | 3.81 Million |
| Change in working capital | 4.25 Million | -11.47 Million | 2.65 Million | -4.27 Million | 7.85 Million | 2.55 Million |
| Other non-cash items | -3.96 Million | 14.63 Million | 2.76 Million | 5.51 Million | -2.99 Million | 273 Thousand |
| Investing Cash Flow | -12.32 Million | -110.22 Million | -49.94 Million | 51.89 Million | -39.32 Million | -74.6 Million |
| Investments in PPE | -250 Thousand | - | -470 Thousand | - | -83 Thousand | -139 Thousand |
| Acquisitions | - | - | 49.47 Million | -101.37 Million | 39.24 Million | 74.46 Million |
| Investment purchases | -77.07 Million | -183.22 Million | -223.34 Million | -102 Thousand | -72.24 Million | -122.13 Million |
| Sales/Maturities of investments | 65 Million | 73 Million | 173.87 Million | 52 Million | 33 Million | 47.66 Million |
| Other Investing Activities | -12.07 Million | -110.22 Million | -49.47 Million | 51.89 Million | -39.24 Million | -74.46 Million |
| Financing Cash Flow | -14 Thousand | 239.38 Million | 187.96 Million | -1000.00 | -210 Thousand | 188.99 Million |
| Debt repayment | - | - | -49.96 Million | -1000.00 | -1000.00 | -49.96 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -1.73 Million | -824 Thousand | 211 Thousand | -211 Thousand | - |
| Common Stock Issuance | -14 Thousand | 241.51 Million | 138.82 Million | - | -211 Thousand | 139.03 Million |
| Other Financing Activities | -14 Thousand | -400 Thousand | 138.82 Million | -211 Thousand | - | 188.99 Million |
| Accounts receivables | -1.09 Million | -516 Thousand | -982 Thousand | -692 Thousand | 367 Thousand | -423 Thousand |
| Accounts payables | 5.91 Million | -9.1 Million | 6.45 Million | -2.65 Million | 6.11 Million | 5.76 Million |
| Inventory | -71 Thousand | -133 Thousand | -381 Thousand | -45 Thousand | -164 Thousand | -172 Thousand |
| Other working capital | -495 Thousand | -1.71 Million | -2.43 Million | -886 Thousand | 1.53 Million | -2.61 Million |
| Cash at beginning of period | 96.49 Million | 22.46 Million | 46.34 Million | 21.11 Million | 102.27 Million | 26 Million |
| Cash at end of period | 35.61 Million | 96.49 Million | 22.46 Million | 22.46 Million | 21.11 Million | 102.27 Million |
| Capital Expenditure | -250 Thousand | - | -470 Thousand | - | -83 Thousand | -139 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -60.87 Million | 74.02 Million | -23.88 Million | 1.34 Million | -81.15 Million | 76.27 Million |
| Free Cash Flow | -48.79 Million | -55.13 Million | -162.36 Million | -50.54 Million | -41.7 Million | -38.25 Million |
NTBL
QLT
GENUSPRIME
0512
SMIN
2331